Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchang
Other Events. On January 6, 2026, the Company announced positive interim data from the Phase 1b clinical trial of zumilokibart (APG777) in patients with mild-to
Financial Statements and Exhibits. (d) Exhibits . The following exhibit is being furnished herewith: EXHIBIT INDEX Exhibit No. Description 99.1 Data Press Relea